Finn RS - Search Results

1

Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases.

Marrero JA, Kulik LM, Sirlin CB, Zhu AX, Finn RS, Abecassis MM, Roberts LR, Heimbach JK. Marrero JA, et al. Among authors: finn rs. Hepatology. 2018 Aug;68(2):723-750. doi: 10.1002/hep.29913. Hepatology. 2018. PMID: 29624699 No abstract available.

2

Percutaneous radiofrequency ablation of hepatocellular carcinoma as a bridge to liver transplantation.

Lu DS, Yu NC, Raman SS, Lassman C, Tong MJ, Britten C, Durazo F, Saab S, Han S, Finn R, Hiatt JR, Busuttil RW. Lu DS, et al. Hepatology. 2005 May;41(5):1130-7. doi: 10.1002/hep.20688. Hepatology. 2005. PMID: 15841454

3

Targeting angiogenesis in hepatocellular carcinoma: focus on VEGF and bevacizumab.

Finn RS, Zhu AX. Finn RS, et al. Expert Rev Anticancer Ther. 2009 Apr;9(4):503-9. doi: 10.1586/era.09.6. Expert Rev Anticancer Ther. 2009. PMID: 19374603 Review.

4

Drug therapy: sorafenib.

Finn RS. Finn RS. Hepatology. 2010 May;51(5):1843-9. doi: 10.1002/hep.23676. Hepatology. 2010. PMID: 20432260 No abstract available.

5

Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report.

Clavien PA, Lesurtel M, Bossuyt PM, Gores GJ, Langer B, Perrier A; OLT for HCC Consensus Group. Clavien PA, et al. Lancet Oncol. 2012 Jan;13(1):e11-22. doi: 10.1016/S1470-2045(11)70175-9. Epub 2011 Oct 31. Lancet Oncol. 2012. PMID: 22047762 Free PMC article.

6

Molecular subtype and response to dasatinib, an Src/Abl small molecule kinase inhibitor, in hepatocellular carcinoma cell lines in vitro.

Finn RS, Aleshin A, Dering J, Yang P, Ginther C, Desai A, Zhao D, von Euw E, Busuttil RW, Slamon DJ. Finn RS, et al. Hepatology. 2013 May;57(5):1838-46. doi: 10.1002/hep.26223. Epub 2013 Apr 1. Hepatology. 2013. PMID: 23299860

7

Extending survival with the use of targeted therapy in the treatment of hepatocellular carcinoma.

Gish RG, Finn RS, Marrero JA. Gish RG, et al. Among authors: finn rs. Clin Adv Hematol Oncol. 2013 Apr;11 Suppl 5:1-22; quiz 2 p following p22. Clin Adv Hematol Oncol. 2013. PMID: 23881427

8

Phase I study investigating everolimus combined with sorafenib in patients with advanced hepatocellular carcinoma.

Finn RS, Poon RT, Yau T, Klümpen HJ, Chen LT, Kang YK, Kim TY, Gomez-Martin C, Rodriguez-Lope C, Kunz T, Paquet T, Brandt U, Sellami D, Bruix J. Finn RS, et al. J Hepatol. 2013 Dec;59(6):1271-7. doi: 10.1016/j.jhep.2013.07.029. Epub 2013 Aug 6. J Hepatol. 2013. PMID: 23928403 Clinical Trial.

9

A phase II and biomarker study of ramucirumab, a human monoclonal antibody targeting the VEGF receptor-2, as first-line monotherapy in patients with advanced hepatocellular cancer.

Zhu AX, Finn RS, Mulcahy M, Gurtler J, Sun W, Schwartz JD, Dalal RP, Joshi A, Hozak RR, Xu Y, Ancukiewicz M, Jain RK, Nugent FW, Duda DG, Stuart K. Zhu AX, et al. Among authors: finn rs. Clin Cancer Res. 2013 Dec 1;19(23):6614-23. doi: 10.1158/1078-0432.CCR-13-1442. Epub 2013 Oct 2. Clin Cancer Res. 2013. PMID: 24088738 Free PMC article. Clinical Trial.

10

Survival after sorafenib: expect the unexpected.

Finn RS. Finn RS. J Hepatol. 2014 Feb;60(2):243-4. doi: 10.1016/j.jhep.2013.10.031. Epub 2013 Nov 9. J Hepatol. 2014. PMID: 24216446 Free article. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

247 results

Search Page